KR20190060787A - 카나비노이드 수용체 결합 리간드를 포함하는 조성물 - Google Patents

카나비노이드 수용체 결합 리간드를 포함하는 조성물 Download PDF

Info

Publication number
KR20190060787A
KR20190060787A KR1020197010976A KR20197010976A KR20190060787A KR 20190060787 A KR20190060787 A KR 20190060787A KR 1020197010976 A KR1020197010976 A KR 1020197010976A KR 20197010976 A KR20197010976 A KR 20197010976A KR 20190060787 A KR20190060787 A KR 20190060787A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
thc
cannabinoid receptor
receptor binding
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197010976A
Other languages
English (en)
Korean (ko)
Inventor
베른하르트 귄터
프랑크 로셔
손자 크로서
필립 스티븐
Original Assignee
노바리크 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노바리크 게엠베하 filed Critical 노바리크 게엠베하
Publication of KR20190060787A publication Critical patent/KR20190060787A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020197010976A 2016-09-28 2017-09-27 카나비노이드 수용체 결합 리간드를 포함하는 조성물 Ceased KR20190060787A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP16191194.6 2016-09-28
EP16191194 2016-09-28
EP17168172 2017-04-26
EP17168172.9 2017-04-26
PCT/EP2017/074545 WO2018060282A1 (en) 2016-09-28 2017-09-27 Compositions comprising a cannabinoid receptor binding ligand

Publications (1)

Publication Number Publication Date
KR20190060787A true KR20190060787A (ko) 2019-06-03

Family

ID=59966776

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197010976A Ceased KR20190060787A (ko) 2016-09-28 2017-09-27 카나비노이드 수용체 결합 리간드를 포함하는 조성물

Country Status (10)

Country Link
US (1) US20190343793A1 (OSRAM)
EP (2) EP3518921B1 (OSRAM)
JP (1) JP2019534867A (OSRAM)
KR (1) KR20190060787A (OSRAM)
CN (1) CN109803650A (OSRAM)
AU (1) AU2017333420A1 (OSRAM)
BR (1) BR112019006194A2 (OSRAM)
CA (1) CA3036313A1 (OSRAM)
MX (1) MX2019003544A (OSRAM)
WO (1) WO2018060282A1 (OSRAM)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10045996B2 (en) 2010-03-17 2018-08-14 Novaliq Gmbh Pharmaceutical composition for treatment of increased intraocular pressure
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
BR112015005008B1 (pt) 2012-09-12 2022-04-19 Novaliq Gmbh Composições de alcano semifluorado
CN104619314B (zh) 2012-09-12 2017-09-22 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
CN114028560A (zh) 2013-07-23 2022-02-11 诺瓦利克有限责任公司 稳定的抗体组合物
CN113662929A (zh) 2015-09-30 2021-11-19 诺瓦利克有限责任公司 用于眼部给药的半氟化化合物
CN108348777B (zh) 2015-09-30 2020-04-28 诺瓦利克有限责任公司 半氟化化合物和其组合物
KR102122887B1 (ko) 2016-05-03 2020-06-16 뉴마 레스퍼러토리 인코포레이티드 유체들의 폐기관계로의 전달을 위한 액적 전달 디바이스 및 사용 방법
USRE50060E1 (en) 2016-06-23 2024-07-30 Novaliq Gmbh Topical administration method
ES2969758T3 (es) 2016-09-22 2024-05-22 Novaliq Gmbh Composiciones farmacéuticas para usar en la terapia de la blefaritis
KR20190057338A (ko) 2016-09-23 2019-05-28 노바리크 게엠베하 시클로스포린을 포함하는 안과 조성물
US10732712B2 (en) * 2016-12-27 2020-08-04 Facebook Technologies, Llc Large scale integration of haptic devices
EP3612228B1 (en) 2017-04-21 2023-08-23 Dermaliq Therapeutics, Inc. Iodine compositions
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
MX2020003534A (es) 2017-09-27 2020-07-29 Novaliq Gmbh Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares.
CN111182893A (zh) 2017-10-04 2020-05-19 诺瓦利克有限责任公司 包含f6h8的眼用组合物
CN118203735A (zh) 2017-10-04 2024-06-18 精呼吸股份有限公司 电子呼吸致动式直线型液滴输送装置及其使用方法
CA3082192A1 (en) 2017-11-08 2019-05-16 Pneuma Respiratory, Inc. Electronic breath actuated in-line droplet delivery device with small volume ampoule and methods of use
AU2019228119A1 (en) 2018-03-02 2020-09-10 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
IL276888B2 (en) 2018-03-28 2024-12-01 Novaliq Gmbh Pharmaceutical composition comprising timolol
EP3784246A1 (en) 2018-04-27 2021-03-03 Novaliq GmbH Ophthalmic compositions comprising tafluprost for the treatment of glaucoma
CN112823020A (zh) 2018-10-12 2021-05-18 诺瓦利克有限责任公司 用于治疗干眼病的眼用组合物
KR102534570B1 (ko) * 2019-02-01 2023-05-18 에어리 파마슈티컬즈, 인코포레이티드 근시의 치료를 위한 화합물, 조성물 및 방법
EP3923907B1 (en) 2019-02-13 2024-09-25 Novaliq GmbH Compositions and methods for the treatment of ocular neovascularization
AU2020340561B2 (en) 2019-09-06 2026-01-22 Novaliq Gmbh Ophthalmic composition for the treatment of uveitis
CN115968278A (zh) 2020-05-18 2023-04-14 麦氏生物科技有限公司 脂质-聚合物组合物及使用方法
CA3173494A1 (en) * 2020-09-24 2022-03-31 Michael Foster DAVIS Cannabinoid composition comprising at least 50% carrier
US20230405025A1 (en) * 2020-10-05 2023-12-21 Max Biology Co. Ltd. Cannabinoid-containing compositions and use for treating and preventing diseases
US11191751B1 (en) * 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions
WO2022169788A1 (en) 2021-02-03 2022-08-11 Ads Therapeutics Llc Topical ophthalmological compositions
WO2022271848A1 (en) 2021-06-22 2022-12-29 Pneuma Respiratory, Inc. Droplet delivery device with push ejection
EP4415708A4 (en) * 2021-10-13 2025-07-30 Pneuma Respiratory Inc COMPOSITIONS FOR THE ADMINISTRATION OF CANNABINOIDS
US20260033533A1 (en) 2022-07-18 2026-02-05 Pneuma Respiratory, Inc. Small step size and high resolution aerosol generation system and method
WO2026037894A1 (en) * 2024-08-15 2026-02-19 Dermaliq Therapeutics, Inc. Semifluorinated alkane compositions for cleaning the skin
WO2026047389A1 (en) * 2024-08-30 2026-03-05 Vicadia Lda Topical delivery of cannabinoid-based formulations for ocular allergy and inflammation in ophthalmic diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19536504C2 (de) * 1995-09-29 1999-09-23 H Meinert Verwendung fluorierter Alkane
EP2046290A4 (en) 2006-08-04 2011-08-17 Insys Therapeutics Inc AQUEOUS DRONABINOL FORMULATIONS
US8222292B2 (en) 2007-08-06 2012-07-17 Insys Therapeutics, Inc. Liquid cannabinoid formulations
PL2352497T3 (pl) 2008-10-31 2017-08-31 University Of Mississippi Proces przygotowania estrów aminokwasowych delta-9-thc
AT509000B1 (de) * 2009-10-23 2012-12-15 Rausch Peter Wasserlösliche zubereitungen von cannabinoiden und cannabispräparaten und deren anwendungen
EP2335735A1 (en) * 2009-12-14 2011-06-22 Novaliq GmbH Pharmaceutical composition for treatment of dry eye syndrome
EP2444063A1 (en) * 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
US8758826B2 (en) 2011-07-05 2014-06-24 Wet Inc. Cannabinoid receptor binding agents, compositions, and methods
BR112015005008B1 (pt) * 2012-09-12 2022-04-19 Novaliq Gmbh Composições de alcano semifluorado
CN104619314B (zh) * 2012-09-12 2017-09-22 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
US9265809B2 (en) 2013-10-09 2016-02-23 Johnson Living Trust dated October 26, 2011, Leonidas A. Johnson, Trustee Methods and compositions for treating and preventing signs or symptoms of eye disease
ES2784229T3 (es) 2013-11-20 2020-09-23 Panag Pharma Inc Composiciones y procedimientos para el tratamiento de la inflamación y el dolor ocular
MA41299A (fr) 2014-12-30 2017-11-07 Axim Biotechnologies Inc Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite

Also Published As

Publication number Publication date
BR112019006194A2 (pt) 2019-06-18
CA3036313A1 (en) 2018-04-05
EP3518921B1 (en) 2021-08-11
CN109803650A (zh) 2019-05-24
WO2018060282A1 (en) 2018-04-05
MX2019003544A (es) 2019-09-19
AU2017333420A1 (en) 2019-04-04
JP2019534867A (ja) 2019-12-05
US20190343793A1 (en) 2019-11-14
EP3698785A1 (en) 2020-08-26
EP3518921A1 (en) 2019-08-07

Similar Documents

Publication Publication Date Title
EP3518921B1 (en) Compositions comprising a cannabinoid receptor binding ligand
US20260115172A1 (en) Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases
KR101652714B1 (ko) 안구건조증 치료용 약학 조성물
EP3488847B1 (en) Semifluorinated alkane compositions
MX2012010684A (es) Composicion farmaceutica para el tratamiento de la presion intraocular incrementada.
HK40036791A (en) Compositions comprising a cannabinoid receptor binding ligand
HK40008248A (en) Compositions comprising a cannabinoid receptor binding ligand
HK40009538B (en) Semifluorinated alkane compositions
HK1240112B (en) Semifluorinated alkane compositions for use in the treatment of keratoconjunctivitis sicca
HK1172269B (en) Pharmaceutical composition for treatment of dry eye syndrome

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190417

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200928

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220125

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220401

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220125

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I